HIV positive pregnant women develop strong resistance to Nevarpin, the drug in use nowNew course of action after
The National AIDS Control Organisation (NACO) is likely to change the current single drug therapy into multi drug therapy currently used in the treatment of HIV positive pregnant women.
Resistance has been developed by patients against Nevarpin, the only medicine which is used to prohibit the transmission of the deadly virus from the mother to the foetus.
This has been proved by research done recently by National AIDS Research Institute (NARI). Elaborating on this, Dr R S Paranjape, director, NARI told Pune Mirror, “NACO had asked NARI to conduct research to find out whether a single dose of Nevarpin develops any resistance in the HIV virus.
NARI had studied and tested the blood samples of 100 pregnant women from Pune and Mumbai as part of this. The research found that after six to eight weeks of delivery, 15.6 per cent of the blood samples were found to have developed resistance against the HIV virus.
Considering the findings of this research it is now clear that there is a need for multi–drug therapy in the treatment of HIV positive pregnant women. Single drug therapy is not as effective in the treatment of a life– threatening virus like HIV as it was expected earlier.”
Dr Paranjape also added that usage of a double or multi–drug therapy could restrict the growth of the HIV virus and also prevent the development of resistance to the virus.
Hence, it will be useful in preventing the transmission of the deadly virus from the mother to the foetus. In 2003, another similar study was conducted in which the blood samples of babies of within the age group of two to six months were studied.
Scientist Dr S Tripathi had conducted this study. This research, too, found that 10.2 per cent babies had developed resistance to the drug.
Source: Pune Mirror
Sunday, Mar 26th
Last update:05:44:44 AM IST